Effects of dietary fiber on inflammatory bowel disease

被引:179
作者
Galvez, J [1 ]
Rodríguez-Cabezas, ME [1 ]
Zarzuelo, A [1 ]
机构
[1] Univ Granada, Dept Pharmacol, Sch Pharm, E-18071 Granada, Spain
关键词
dietary fiber; experimental colitis; inflammatory bowel disease; prebiotic; review; short-chain fatty acid;
D O I
10.1002/mnfr.200500013
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The chronic idiopathic inflammatory bowel diseases (IBDs), namely Crohn's disease and ulcerative colitis, appear to be derived from an inappropriate reaction towards a luminal agent, most probably driven by the intestinal microflora, which upregulates the synthesis and release of different pro-inflammatory mediators, thus contributing to tissue damage that characterizes these intestinal conditions. Several studies have reported that IBD is associated with impairment in short-chain fatty acid (SCFA) production, mainly acetate, propionate, and butyrate. They are produced in the large bowel by anaerobic bacterial fermentation of undigested dietary carbohydrates and fiber polysaccharides, with butyrate being considered as the major fuel source for colonocytes. These SCFAs have been proposed to play a key role in the maintenance of colonic homeostasis. Therefore, it is reasonable to consider therapeutic approaches that increase colonic SCFA production, as it can be achieved by administration of dietary fiber to IBD patients. Unfortunately, there is quite limited documentation of efficacy of dietary fiber in properly designed trials. This review discusses the rationale, available evidence for the use of dietary fiber and its mechanisms of action in the treatment and prevention of IBDs.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 79 条
[1]   SPONTANEOUS INTESTINAL INFLAMMATION AND NITRIC-OXIDE METABOLISM IN HLA-B27 TRANSGENIC RATS [J].
AIKO, S ;
GRISHAM, MB .
GASTROENTEROLOGY, 1995, 109 (01) :142-150
[2]  
Aiko S, 1998, J PHARMACOL EXP THER, V284, P722
[3]   Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis [J].
Allan, ES ;
Winter, S ;
Light, AM ;
Allan, A .
GUT, 1996, 38 (06) :886-893
[4]  
Andoh A, 1999, CLIN EXP IMMUNOL, V118, P23
[5]  
Andus T, 2000, HEPATO-GASTROENTEROL, V47, P29
[6]   Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease [J].
Bassaganya-Riera, J ;
Reynolds, K ;
Martino-Catt, S ;
Cui, YZ ;
Hennighausen, L ;
Gonzalez, F ;
Rohrer, J ;
Benninghoff, AU ;
Hontecillas, R .
GASTROENTEROLOGY, 2004, 127 (03) :777-791
[7]   Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial [J].
Breuer, RI ;
Soergel, KH ;
Lashner, BA ;
Christ, ML ;
Hanauer, SB ;
Vanagunas, A ;
Harig, JM ;
Keshavarzian, A ;
Robinson, M ;
Sellin, JH ;
Weinberg, D ;
Vidican, DE ;
Flemal, KL ;
Rademaker, AW .
GUT, 1997, 40 (04) :485-491
[8]   The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression [J].
Camuesco, D ;
Comalada, M ;
Rodriguez-Cabezas, ME ;
Nieto, A ;
Lorente, MD ;
Concha, A ;
Zarzuelo, A ;
Gálvez, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (07) :908-918
[9]   Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes [J].
Cavaglieri, CR ;
Nishiyama , A ;
Fernandes, LC ;
Curi, R ;
Miles, EA ;
Calder, PC .
LIFE SCIENCES, 2003, 73 (13) :1683-1690
[10]   BUTYRATE METABOLISM IN THE TERMINAL ILEAL MUCOSA OF PATIENTS WITH ULCERATIVE-COLITIS [J].
CHAPMAN, MAS ;
GRAHN, MF ;
HUTTON, M ;
WILLIAMS, NS .
BRITISH JOURNAL OF SURGERY, 1995, 82 (01) :36-38